RESEARCH ARTICLE

Computational screening for potential drug candidates against the SARS-CoV-2 main protease [version 1; peer review: 1 approved, 1 approved with reservations]

Bruno Silva Andrade ¹, Preetam Ghosh², Debmalya Barh ³, Sandeep Tiwari⁴, Raner José Santana Silva⁵, Wagner Rodrigues de Assis Soares⁶, Tarcisio Silva Melo¹, Andria Santos Freitas⁵, Patrícia González-Grande⁵, Lucas Sousa Palmeira¹, Luiz Carlos Junior Alcantara ^{4,7}, Marta Giovanetti^{4,7}, Aristóteles Góes-Neto ⁸, Vasco Ariston de Carvalho Azevedo⁴

¹Laboratório de Bioinformática e Química Computacional, Departamento de Ciências Biológicas, Universidade Estadual do Sudoeste da Bahia (UESB), Jequié, Bahia, 45205-490, Brazil

²Department of Computer Science, Virginia Commonwealth University, Richmond, VA, 23284, USA

³Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Purba Medinipur, India

⁴Laboratório de Genética Celular e Molecular, Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, MG, Brazil

⁵Programa de Pós-graduação em Genética e Biologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, BA, Brazil

⁶Departamento de Saúde II, Universidade Estadual do Sudoeste da Bahia., Jequié, BA, Brazil

⁷Laboratório de Flavivírus, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil

⁸Laboratório de Biologia Molecular e Computacional de Fungos, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil

v1 First published: 04 Jun 2020, 9:514
<https://doi.org/10.12688/f1000research.23829.1>
 Latest published: 21 Dec 2020, 9:514
<https://doi.org/10.12688/f1000research.23829.2>

Abstract

Background: SARS-CoV-2 is the causal agent of the current coronavirus disease 2019 (COVID-19) pandemic. They are enveloped, positive-sense, single-stranded RNA viruses of the Coronaviridae family. Proteases of SARS-CoV-2 are necessary for viral replication, structural assembly, and pathogenicity. The approximately 33.8 kDa M^{Pro} protease of SARS-CoV-2 is a non-human homologue and is highly conserved among several coronaviruses, indicating that M^{Pro} could be a potential drug target for Coronaviruses.

Methods: Herein, we performed computational ligand screening of four pharmacophores (OEW, remdesivir, hydroxychloroquine and N3) that are presumed to have positive effects against SARS-CoV-2 M^{Pro} protease (6LU7), and also screened 50,000 natural compounds from the ZINC Database dataset against this protease target.

Results: We found 40 pharmacophore-like structures of natural compounds from diverse chemical classes that exhibited better affinity of docking as compared to the known ligands. The 11 best

Open Peer Review

Approval Status

	1	2
version 2		
(revision)		
21 Dec 2020		
version 1		
04 Jun 2020		

1. Murtaza M. Tambuwala , Ulster University, Coleraine, UK

2. Alaa A A Aljabali , Yarmouk University, Irbid, Jordan
 Yarmouk University, Irbid, Jordan

selected ligands, namely ZINC1845382, ZINC1875405, ZINC2092396, ZINC2104424, ZINC44018332, ZINC2101723, ZINC2094526, ZINC2094304, ZINC2104482, ZINC3984030, and ZINC1531664, are mainly classified as beta-carboline, alkaloids, and polyflavonoids, and all displayed interactions with dyad CYS145 and HIS41 from the protease pocket in a similar way as other known ligands.

Conclusions: Our results suggest that these 11 molecules could be effective against SARS-CoV-2 protease and may be subsequently tested *in vitro* and *in vivo* to develop novel drugs against this virus.

Keywords

SARS-CoV-2, protease, virtual screening, pharmacophore, inhibitors, natural compounds

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the **Bioinformatics** gateway.

This article is included in the **Emerging Diseases** and **Outbreaks** gateway.

This article is included in the **Coronavirus** collection.

Corresponding author: Bruno Silva Andrade (bandrade@uesb.edu.br)

Author roles: **Silva Andrade B:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Ghosh P:** Data Curation, Formal Analysis, Writing – Review & Editing; **Barh D:** Formal Analysis, Writing – Review & Editing; **Tiwari S:** Formal Analysis, Writing – Review & Editing; **José Santana Silva R:** Data Curation, Formal Analysis, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing; **Rodrigues de Assis Soares W:** Conceptualization, Data Curation, Formal Analysis, Writing – Original Draft Preparation, Writing – Review & Editing; **Silva Melo T:** Formal Analysis, Writing – Original Draft Preparation; **Santos Freitas A:** Formal Analysis, Writing – Original Draft Preparation; **González-Grande P:** Writing – Original Draft Preparation; **Sousa Palmeira L:** Data Curation, Formal Analysis, Investigation; **Carlos Junior Alcantara L:** Writing – Review & Editing; **Giovanetti M:** Writing – Review & Editing; **Góes-Neto A:** Conceptualization, Formal Analysis, Writing – Original Draft Preparation, Writing – Review & Editing; **Ariston de Carvalho Azevedo V:** Conceptualization, Formal Analysis, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the National Council for Scientific and Technological Development (CNPq) of Brazil: Luiz Alcantara receives research grant: 304387/2017-7; Aristóteles Góes-Neto receives research: grant 310764/2016-5; Vasco Azevedo receives research grant: 305093/2015-0.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Silva Andrade B *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Silva Andrade B, Ghosh P, Barh D *et al.* **Computational screening for potential drug candidates against the SARS-CoV-2 main protease [version 1; peer review: 1 approved, 1 approved with reservations]** F1000Research 2020, 9:514 <https://doi.org/10.12688/f1000research.23829.1>

First published: 04 Jun 2020, 9:514 <https://doi.org/10.12688/f1000research.23829.1>

Introduction

Coronaviruses (CoVs) are enveloped, positive-sense, single-stranded RNA viruses of the Coronaviridae family¹. Based on their antigenic properties, they were classified into three main groups²: i) alpha-CoVs, responsible for gastrointestinal disorders; ii) beta-CoVs, which include: (a) Bat coronavirus (BCoV), (b) human severe acute respiratory syndrome (SARS) virus, (c) Middle Eastern respiratory syndrome (MERS) virus; and iii) gamma-CoVs, which mainly infect avian species. The most well-known of these coronaviruses is the SARS-CoV, responsible for causing an outbreak in 2002–2003³ and MERS-CoV, causing severe respiratory symptoms, which was identified in 2012⁴.

In December 2019, a series of unusual pneumonia cases caused by a novel coronavirus, recently renamed as SARS-CoV-2, was identified in Wuhan, China^{5,6}. The disease caused by SARS-CoV-2 is now called COVID-19, and displays vast pathophysiological aspects, which include symptoms, such as fever and coughing, and severe acute respiratory failure⁷. Since the infection crossed geographical barriers, the World Health Organization (WHO) declared a pandemic situation in March 2020, reaching a worldwide mortality rate of approximately 3%⁶.

The SARS-CoV-2 ORF1ab code for polyprotein 1ab (pp1ab), where the main protease M^{pro} is found, which is similar to a key enzyme in the processing of the picornavirus family polyprotein. The protease M^{pro}, digests more than 11 conserved sites starting from its autolytic cleavage in pp1ab, and is a protein with extreme functional importance in the viral cycle⁸. Due to its great importance in the coronavirus cycle, the M^{pro} sequence of SARS-CoV-2 shows more than 90% similarity with the enzymes of other coronaviruses⁹ and shares 96% identity with SARS-CoV. Although M^{pro} is conserved among SARS-CoVs, it has a loop that can make it difficult for an inhibitor to access the catalytic pocket, and mutations in this loop can generate drug resistance¹⁰. Thus, even though M^{pro} is one of the most conserved SARS-CoV group proteins, point mutational aspects can lead to a possible drug resistance, so that a wide range of inhibitor options is necessary for the treatment of COVID-19.

ORF1ab is characteristic of members of the Coronaviridae family¹¹ and is equivalent to two-thirds of the SARS-CoV-2 virus genome¹². Each of these ORFs encodes a polyprotein (pp), which, when cleaved by proteases contained in the sequence, will generate 11 proteins (pp1a) and 5 proteins (pp1ab), respectively. The functions associated with these proteins are related to the virus replication processes and the modulation of the immune response in the host, among other essential functions for the development of the pathogen within the host cell⁶.

Virus resistance to drugs can lead to the emergence of new epidemics, such as influenza A virus (IAV). In this case, two drug classes have been related: M2 channel inhibitors (amantadine and rimantadine) and neuraminidase inhibitors (NAIs; oseltamivir, zanamivir, peramivir, and Laninamivir). Both drug classes act by inhibiting proteins that are located in the viral

envelope, and this region is in greater contact with the external environment and is prone to suffer from greater evolutionary pressure and, consequently, mutations¹³. Drug resistance can occur when rapid viral replication is not repressed completely¹⁴. In contrast, virus proteases play a crucial role during virus replication and, therefore, they are a good target for drug discovery¹⁵.

During viral replication, proteases are necessary for the assembly of the viral structure, and there have already been suggested to have relationships with the mechanism of infection and pathogenicity of SARS-CoV-2^{5,16}. Proteases are enzymes found in all cellular organisms and viruses and are classified according to their catalytic nature. Proteases are divided into four groups: serine, cysteine, aspartyl and metalloproteases. Different types of proteases can perform the same activity through different catalytic mechanisms¹⁵, and a protease commonly has a binding site and a catalytic site that are very close in the protein structure¹⁵. Furthermore, proteases are present in several types of viruses and are widely found in human viruses¹⁷.

In coronaviruses, pp1 is essential for the replication of the virus, as it encodes the protease M^{pro}, which is also called the “main protease”^{18,19}. M^{pro} is classified as a chymotrypsin-like cysteine protease (3CLpro), EC: 3.4.19.12,^{9,18}, and the M^{pro} protease of SARS-CoV-2, which has a mass of approximately 33.8 kDa¹⁹, is characterized by a self-cleavage protein^{20,21}. It consists of a homodimer subdivided into two protomers (A and B) that have three distinct domains²². The first and second domains have antiparallel β -sheets while the third domain contains five α -helices forming a globular group, which is connected in parallel with the domain-II through a loop region¹⁹. The M^{pro} of SARS-CoV-2 has a catalytic cleft, consisting of a Cys-His dyad in the place of the protease substrate interaction, which is situated between domains -I and -II¹⁹. It also has non-canonic specificity to the substrate in the C-terminal portion. Furthermore, there is no homologue of M^{pro} in the human genome^{19,23}, and it is highly conserved amongst coronaviruses²⁴. Therefore, M^{pro} is a potential target for studying inhibitors.

Antiviral therapy considers three main approaches for the control and avoidance of viral infections: (a) vaccination, (b) stimulation of host resistance mechanisms, and (c) antiviral chemotherapy. Antivirals are drugs that inhibit certain virus-specific events, such as binding to host cells, which is how SARS-Cov-2 binds to ACE2 and TMPRSS2²⁵, and MERS binds to the DPP415 receptor²⁶. Antiviral chemotherapy can involve interfering with any or all of these viral replication steps. Most antiviral drugs are primarily targeted to the synthesis of nucleic acids in viruses. As viral replication and host cell processes are closely linked, one of the main problems of viral therapy would be to find a drug capable of being selectively toxic only for the virus. Antivirals are frequently more effective in prevention than in the treatment itself, and are ineffective in eliminating latent or non-replicating viruses²⁷. In addition, when selecting an antiviral drug, viral resistance must also be considered since it is one of the main causes of therapeutic failure.

The main classes of antiviral drugs used in clinical therapy to treat systemic viral infections include: a) synthetic nucleosides (e.g. acyclovir, famciclovir, ganciclovir, valganciclovir, and valganciclovir); b) pyrophosphate analogs (e.g. foscarnet); c) drugs for syncytial virus and influenza A (e.g. amantadine and rimantadine hydrochloride and ribavirin); d) nucleoside reverse transcriptase inhibitors (NRTI; e.g. abacavir, didanosine, emtricitabine, stavudine, lamivudine, zidovudine, tenofovir in combination with NRTI); e) non-nucleoside reverse transcriptase inhibitors (NNRTI; e.g. delavirdine, efavirenz, nevirapine); and f) protease inhibitors (e.g. amprenavir, atazanavir, darunavir, fosamprenavir, lopinavir and ritonavir, nelfinavir mesylate, saquinavir mesylate, ritonavir, indinavir sulfate and tipranavir)^{28,29}

Computational studies of inhibitors that may reduce viral replication is a fast way for proposing drug candidates that can contribute to a reduction in severity and spread of the disease. Moreover, the use of antiviral compounds can assist in the prophylaxis of SARS-CoV-2 and reduce its spread³⁰. Therefore, screening for potential viral protease inhibitors may assist in the selection of new drugs with antiviral potential for SARS-CoV-2.

Methods

Ligand screening

For this study, we employed both ligand-based virtual screening (LBVS) and receptor-based virtual screening (RBVS) approaches, considering 50,000 structures of natural compounds from the ZINC Database, which has more than 900 million structures deposited, and includes millions of drug-like compounds that can be obtained for *in vitro* and *in vivo* tests³¹. The ZINC molecules that were downloaded were those restricted to absorption, distribution, metabolism, excretion and toxicity characteristics (ADMET) for drug likeness: no more than 5 hydrogen bond donors, no more than 10 hydrogen bond acceptors, molecular weight between 160 and 500 Daltons and logP between -0.4 and 5.6^{32,33}. For LBVS, we defined four known drugs divided in the following groups: 1) peptide-like crystallographic ligands (N3 and OEW); and 2) repurposed drugs (remdesivir (nucleoside) and hydroxychloroquine) for chemical comparison with our database.

Crystallographic ligand structures were obtained from their corresponding PDB files 6LU7 (N3) and 6Y7M (OEW). Additionally, these structures were used for re-docking validations. In the LBVS process, we used a simple run with vROCS (OpenEye)³⁴ for generating queries with the pharmacophoric map with the stereochemical characteristics for each known ligand. Another option for pharmacophore generation and searching is the free software PharmaGist³⁵. Afterwards, we submitted each ligand query for searching similar pharmacophore-like molecules using the Tanimoto Combo algorithm^{36,37} with a cut-off of 1.0, which returned the best 1,000 hits for each round. This procedure was repeated three times for each query, and, subsequently, redundant structures were discarded, generating, in the end, a total of 4,000 similar molecules for the docking experiment.

Docking studies

Considering PDB validation indices as crystallographic resolution, Ramachandran outliers, clash score, and release date, we selected the structure 6LU7 for RBVS, which is complexed with the peptide-like inhibitor N3¹⁹. Furthermore, 6LU7 and 6Y7M³⁸ were used for re-docking validations with its corresponding crystallographic inhibitors.

The best LBVS hits were submitted to molecular docking calculations with 6LU7 structure using Autodock 4.2 virtual screening protocol³⁹. Ligand structures were prepared for virtual screening using Raccoon plugin⁴⁰ for Autodock Tools⁴⁰ according to the standard protocol³⁷, as well as the 6LU7 structure. The gridbox was defined on the active site region, considering the amino acids THR 190, GLU 166, GLN 189, GLY 143, HIS 163, HIS 164, CYS 145, PHE 140, and with accordance with previous studies with the crystallographic structure of the SARS-CoV-2 main protease^{19,38,41}. Each docking run was performed three times using the following specifications: flexible docking and Lamarckian Genetic Algorithm with 2,500,000 generations. Afterwards, the 10 best docking hits were selected using the Autodock Tools script *summarize_results4.py*, which can classify the best hits according to their lowest energy clustering conformations and root mean square deviation (RMSD) values. The results were organized according to the ligand pharmacophore relationship with the known structures in Table 2. Docking and re-docking results were evaluated at each docking position inside the 6LU7 active site using Pymol 2.1⁴² and UCSF Chimera 1.14⁴³ in order to confirm molecule interactions with the amino acids within the protease active site. Furthermore, 2D interaction maps were generated by Discovery Studio 2019⁴⁴. Another option for 2D map generation is the LigPlot+ software⁴⁵.

Results

LBVS

Different pharmacophoric characteristics were generated for each known ligand (Figure 1), which allowed us to find molecules included in different chemical classifications and amplify the number of possible drug candidates. Table 1 shows the pharmacophoric characteristics for each known 6LU7 inhibitor, which permitted us to find natural ligands with pharmacophore-like regions. Additionally, we used the ADMET characteristics for molecular weight and LogP that are important for molecular druggability.

Ligand based virtual screening and docking calculations of ZINC database compounds revealed the 40 best pharmacophore-like ligands that belong to different chemical classes, namely beta-carboline alkaloids, indole alkaloids, lupin alkaloids, harmala alkaloids, polyflavonoids, anthracenes, angular pyranocoumarins, and flavonoid-3-O-glycosides. Table 2 shows the detailed results on the average affinity energies, ZINC identification, and chemical classification of each selected ligand.

For selecting the best pharmacophore-like drug-candidates, we considered evaluating lower affinity energy values, as well as interactions with residues of the active site within the target. As can be seen in Figure 2A, all pharmacophore-like OEW

Figure 1. Pharmacophore representation for each known drug used for virtual screening. (A) OEW, (B) N3, (C) remdesivir and (D) hydroxychloroquine. In red spheres: hydrogen acceptors; blue spheres: hydrogen donors; yellow spheres: hydrophobic; and green spheres: aromatic.

Table 1. Pharmacophoric characteristics for each known inhibitor used for screening natural ligands from the ZINC Database.

Inhibitor	Hb.A.	Hb.D.	Aromatic	Hydrophobic	M.W.	LogP
OEW	7	5	3	1	663.8	-0.71
N3	6	4	3	2	680.8	2.32
Remdesivir	9	1	4	2	602.6	1.9
Hydroxychloroquine	2	2	2	0	335.9	3.6

Hb.A. = hydrogen acceptor; Hb.D. = hydrogen donor; M.W. = molecular weight.

and HIS41 represented interactions of the type π , π - π stacked and π -alkyl with the entire beta-carboline group, which was composed of three hydrophobic rings. The remaining residues were of the π -sigma type, hydrogen-carbon acceptors, and halogen acceptors from residues THR25, THR26, as well as other residues from the active site GLU166, GLN189, GLY143, HYS164, respectively.

Ligand ZINC1875405 represented two hydrogen bonding interactions with residues THR25 and PHE140. Additionally, four more polar interactions of the type π - π stacked, π -aqua,

ligand molecules formed a complex with the active pocket of 6LU7. The three best OEW ligands (ZINC1845382, ZINC1875405, ZINC2092396) are shown in complex with COVID-19 protease in Figure 2B–D with the detailed 2D interaction map. In this case, these top three hits are included in the beta-carboline alkaloid class.

RBVS

The intermolecular interactions carried out by ligand ZINC1845382 exhibited a hydrogen bond with the residue of the active PHE140 protease site. The catalytic residues CYS145

Table 2. The 40 best molecule hits of COVID-19 main protease inhibitor candidates from a dataset of 50,000 natural compounds from the ZINC Database.

Known Drug	Ligand	Energ. Binding (Kcal/Mol)	Classification	RMSD Å	Pred. IC50 (uM)	Exp. IC50 (uM)
OEW	OEW*	-8.86	Peptide-like	1.97	0.320	0.670
	ZINC1845382	-10.2	β -carboline Alkaloid			
	ZINC1875405**	-10.1	β -carboline Alkaloid			
	ZINC2092396	-9.8	β -carboline Alkaloid			
	ZINC1900463	-9.8	β -carboline Alkaloid			
	ZINC2149492	-9.8	β -carboline Alkaloid			
	ZINC2112405	-9.7	β -carboline Alkaloid			
	ZINC2095426	-9.7	β -carboline Alkaloid			
	ZINC2094306	-9.6	β -carboline Alkaloid			
	ZINC2144677	-9.6	Anthracene			
	ZINC1095868	-9.5	Harmala Alkaloids			
	N3*	-9.77	Peptide-like	1.94	0.07	4.67
N3	ZINC2104482	-10.1	β -carboline Alkaloid			
	ZINC3984030	-9.9	Polyflavonoid			
	ZINC1531664	-9.8	Polyflavonoid			
	ZINC2152199	-9.8	β -carboline Alkaloid			
	ZINC4096847	-9.6	Flavonoid-3-O-glycoside			
	ZINC3947428	-9.6	Flavonoid-3-O-glycoside			
	ZINC2092587	-9.6	β -carboline Alkaloid			
	ZINC2115924	-9.5	β -carboline Alkaloid			
	ZINC2110081	-9.5	Lupin Alkaloid			
	ZINC1898165	-9.5	Benzofuran			
	HCQ	-7.90	4-aminoquinoline			
Hydroxychloroquine (HCQ)	ZINC2101723	-10.2	β -carboline Alkaloid			
	ZINC2094526	-9.8	β -carboline Alkaloid			
	ZINC2094304	-9.6	β -carboline Alkaloid			
	ZINC2091604	-9.4	β -carboline Alkaloid			
	ZINC2113496	-9.4	β -carboline Alkaloid			
	ZINC1460216	-9.3	Angular Pyranocoumarin			
	ZINC2123008	-9.2	β -carboline Alkaloid			
	ZINC682759	-9.2	Harmala Alkaloids			
	ZINC2105243	-9.2	β -carboline Alkaloid			
	ZINC2111696	-9.1	β -carboline Alkaloid			
	REMD	-8.28	Nucleoside			

Known Drug	Ligand	Energ. Binding (Kcal/Mol)	Classification	RMSD Å	Pred. IC50 (uM)	Exp. IC50 (uM)
Remdesivir (REMD)	ZINC2104424	-10.6	β-carboline Alkaloid			
	ZINC1875405**	-10.1	β-carboline Alkaloid			
	ZINC44018332	-10.0	Polyflavonoid			
	ZINC2148932	-9.9	β-carboline Alkaloid			
	ZINC2156531	-9.9	Indoles Alkaloid			
	ZINC3197535	-9.9	Polyflavonoid			
	ZINC2102620	-9.9	Indoles Alkaloid			
	ZINC2123402	-9.9	β-carboline Alkaloid			
	ZINC2149488	-9.9	β-carboline Alkaloid			
	ZINC1531664	-9.9	Polyflavonoid			

*Re-docked crystallographic structures.
**Repeated ligand between OEW and Remdesivir pharmacophores.

Figure 2. (A) SARS-CoV-2 main protease complexed with the 10 best hits for OEW pharmacophore molecules. Protomer A is represented in marine blue surface and protomer B in dark pink surface. ZINC1845382 in cyan (B), ZINC1875405 in dark pink (C) and ZINC2092396 in purple (D) inside 6LU7 binding site and their 2D interaction maps with pocket amino acids.

aquil and π -sulfur with residues HIS41, MET49, CYS145 and MET165, respectively, were formed. The other interactions were of hydrophobic van der Waals type.

Ligand ZINC2092396 interacted by hydrogen interaction with the residue PHE140, π and π -alkyl with CYS140, π - π stacked and π -alkyl HIS41, and van der Waals with GLN189, GLY143, HIS164, GLU166. Other interactions occurred with hydrogen bonds by the ligand nitrobenzene group with the ASN142 residue and a π -sulfur interaction of the beta-carboline group with MET165 residue.

The remdesivir pharmacophore-like search returned two beta-carboline alkaloids (ZINC2104424 and ZINC1875405), as well as one polyflavonoid (ZINC44018332), which interacted with the COVID-19 main protease active pocket showing affinity energies below -10.0 kcal/Mol. **Figure 3A–D** shows

the details of all ligand interactions, as well as the top three molecules interaction maps.

Ligand ZINC2104424 also occupied the region of the active site (**Figure 3B**), showing polar interactions π , π -alkyl, π - π stacked and π -sulfur types from beta-carboline with HIS41, MET49, CYS145, and MET165 amino acids. Moreover, an interaction of THR26 halogen with the ligand fluorobenzene group also occurred. Other hydrophobic interactions were van der Waals, mostly with residues of the active site: PHE140, GLY143, HIS163, HIS164, GLU166 and GLN189.

Ligand ZINC1875405 (**Figure 3C**) displayed three hydrogen interactions with the indole group, and two oxygen interactions from a nitrobenzene of THR25, PHE140 AND GLN166, respectively. Several van der Waals-type hydrophobic interactions were found with GLY143, HIS164 and GLN189 amino

Figure 3. (A) SARS-CoV-2 main protease complexed with 10 best hits for remdesivir pharmacophore molecules. Protomer A is represented in green surface, and protomer B in orange surface. ZINC2104424 in cyan (**B**), ZINC1875405 in wheat (**C**) and ZINC44018332 in violet (**D**) inside 6LU7 binding site and their 2D interaction maps with pocket amino acids.

acids. Furthermore, four polar interactions (π , π -alkyl, π - π stacked and π -sulfur) with residues HIS41, MET49, CYS 145 and MET165, respectively, were also retrieved.

Ligand ZINC2092396 (Figure 3D) exhibited two hydrogen interactions with HIS163 and THR26 by its hydroxyl from the flavonoid nucleus, as well as four more π -donor hydrogen bonding interactions with residues TYR54, PHE140, GLY143 and GLU166. Besides, three π -alkyl and π -sulfur interactions made with MET49, CYS145 and MET165 were also retrieved. Other hydrophobic interactions were of van der Waals type.

Figure 4 shows the interactions between 6LU7 active sites and the three best hits from derived molecules of hydroxychloroquine pharmacophore (ZINC2101723, ZINC2094526, ZINC2094304).

These complexes displayed affinity energies varying from -10.2 kcal/Mol to -9.6 kcal/Mol, and all the ligands were classified as beta-carboline alkaloid derivatives.

The beta-carboline group of the ligand ZINC2101723 (Figure 4B) formed four π -alkyl, alkyl and π -sulfur type interactions with HIS41, MET49, CYS145 and MET165 residues, as well as other hydrophobic interactions from its naphthalene and beta-carboline groups with the active site amino acids PHE140, GLY143, HIS163 E164, GLU166 and GLN189. Ligand ZINC2094526 (Figure 4C) displayed a hydrogen bond interaction with PHE140 by its nitrobenzene group. Five polar interactions (π -sigma, π -aquil, π - π stacked and π -sulfur) were observed with residues THR25, HIS41, MET49, CYS145 and MET165. For ligand ZINC2094304 (Figure 4D), two hydrogen bonds with residues PHE140 and GLU166 by

its nitrobenzene group were formed. In addition, this ligand formed four polar interactions (π - π stacked, π -alkyl, alkyl and π -sulfur) with residues HIS41, MET49, CYS145 and MET165, respectively. Other van der Waals type interactions could also be identified.

The N3 pharmacophore revealed one beta-carboline alkaloid (ZINC2101723) and two polyflavonoids (ZINC2094526 and ZINC2094304). This group displayed affinity energies ranging from -9.8 kcal/Mol to -10.1 kcal/Mol. In **Figure 5**, the best complex interactions with the protease, as well as their positions inside the binding pocket are depicted.

Ligand ZINC2104482 (**Figure 5B**) formed a large number of hydrophobic interactions (14 van der Waals interactions), surrounding the active site amino acid, such as GLY143, HIS164, GLU166 and GLN189. Furthermore, this ligand formed three π -alkyl and alkyl bonds with HIS41, MET49, CYS145 residues. Ligand ZINC3984030 (**Figure 5C**) exhibited three hydrogen bonds with THR26, TYR54 and

GLU166 residues by OH groups of flavonoid nuclei. A π -donor hydrogen bond interaction of the GLY143 residue was also observed. Moreover, three polar interactions (π - π stacked, π -alkyl and π -sulfur) were identified with HIS41, CYS145 and MET165. The rest of the interactions were van der Waals type. Ligand ZINC1531664 (**Figure 5D**) showed a hydrogen bond by its OH group TYR54. Additionally, four π -donor hydrogen bond and hydrogen carbon bond interactions with residues PHE140, GLY143, GLU166 also occurred. Two polar interactions of the type π -alkyl and π -sulfur were observed with MET49, CYS145, and MET165, and the other hydrophobic interactions were of van der Waals type.

Re-docking validation experiments

Crystallographic ligands N3 and OWE were re-docked with their respective M^{pro} structures 6LU7 and 6Y7M. As can be seen in **Figure 6A**, both N3 and OEW molecules bound into similar positions in comparison to their original crystallographic forms. The **Figure 6B** depicts the best clustering conformations graph for N3 with a free energy of binding ranging

from -1.83 kcal/Mol to -9.7 kcal/Mol. **Figure 6C** shows the superposition between the crystalized and re-docked N3 structure. Even though N3 is peptide-like with 13 rotatable bonds, it presented an RMSD of 1.94 Angstroms for its best

conformation (**Table 2**). OEW re-docking is shown in **Figure 6D** in the same way as for N3 where both the crystallized and docked structures bound into the same pocket. Conformational population of OEW clustering results returned a free energy of

Figure 6. Re-docking validations for N3 and OEW. (A) crystallographic (hot pink) and re-docked (green) N3 inhibitor of the 6LU7 SARS-CoV-2 M^{pro} inside its binding pocket; (B) N3 docking best clustering conformations; (C) aligned N3 crystallized (yellow) and re-docked (cyan). (D) crystallographic (pink) and re-docked (purple) OEW inhibitor of the 6LU7 SARS-CoV-2 M^{pro} inside its binding pocket; (E) OEW docking best clustering conformations; (F) aligned OEW crystallized (green) and re-docked (red).

binding ranging from -7.0 kcal/Mol to -11.5 kcal/Mol but, on the other hand, the structure with binding energy of -8.86 kcal/Mol exhibited the smallest RMSD value (Figure 6E). Additionally, OEW presented an RMSD of 1.97 Å in comparison to its crystallized form (Figure 6F).

Discussion

Docking results revealed 39 pharmacophore-like natural ligands, which can be used as drug candidates for inhibiting SARS-CoV-2 main protease activity. Furthermore, we ranked the three best candidates for each known ligand pharmacophore as the best potential drug molecules (and totaling 12 molecules) for *in vitro* and *in vivo* assays purposes, but not excluding the other 28 molecules. For these cases, ligands are included in two most expressive chemical classes: β -carboline alkaloids and polyflavonoids. Additionally, all ligands exhibiting better affinity energies than the known drugs was used as references for construction of pharmacophoric characteristics: OEW⁶, remdesivir⁴⁶, hydroxychloroquine⁴⁷, and N3¹⁹.

The groups of OEW and hydroxychloroquine pharmacophores presented their three most promising ligands classified as β -carboline alkaloids. This class of molecules is reported by different authors with antiviral activities. According to Gonzalez *et al.*⁴³, β -carboline Alkaloids are widely distributed in nature, and its derivatives exhibited activity against Herpes Simplex Viruses by blocking virus replication. Additionally, Gonzalez *et al.*⁴³ demonstrated the action of these alkaloids in dengue virus RNA replication. Furthermore, several other studies suggest alkaloid activity against viral proteases^{48–50}. Similarly, remdesivir pharmacophore revealed two β -carboline alkaloids (ZINC2104424 and ZINC1875405). In addition, we detected a polyflavonoid (ZINC44018332) as one probable active molecule from a different class against SARS-CoV-2 main protease, and several authors have already described flavonoid activity as viral protease inhibitors^{51–53}, as well as antiviral molecules acting in different target classes^{52,54–56}. N3 pharmacophore displayed two flavonoids as the best molecules and just one β -carboline alkaloid. These results indicate that both classes of molecules could be explored for *in vitro* and *in vivo* tests to evaluate their potential antiviral activities for not only SARS-CoV-2 but also for other viruses of medical interest.

Other classes of molecules were found in our screening for protease activity that were previously described in antiviral studies: anthracenes⁵⁷, angular pyranocoumarin^{58,59}, and flavonoid-3-O-glycoside⁶⁰. Interaction maps of these complexes are available as *Extended data*⁶¹.

All the known ligands (OEW, remdesivir, hydroxychloroquine and N3), which were used for validating our computational screening, exhibited worse affinity energies in docking calculations (ranging from -7.8 kcal/Mol to -5.2 kcal/Mol) than the screened natural compounds (ranging from -10.6 kcal/Mol to -9.1 kcal/Mol). Moreover, all the 40 selected ligands docked inside M^{pro} active site, as previously described in several antiviral studies, and interacted in the region of connection

between domains I and II with amino acids HIS41 and CYS145^{18,19,22,38,41,62}.

Novel M^{pro} ketoamide inhibitors were recently proposed, including the OEW ligand (ligand 13b) that was used in our study, and the authors detected a reduction in RNA replication in human cells infected with SARS-CoV-2, and also described binding interactions with its main protease. Besides, the same study indicated a ketoamide as a probable drug candidate against this virus³⁸.

In a recent study, authors have proposed the peptidomimetic molecule N3 as a drug candidate against COVID-19, and described its binding interactions with the crystallographic structures of SARS-CoV-2 and other viral proteases. Their study reported that N3 can bind in all the active pockets from the main proteases of HCoV-NL63, SARS-CoV, and MERS-CoV⁶³.

Other molecules have also been tested as antivirals for effectiveness in inhibiting SARS-CoV-2 replication in cell culture. Two drugs exhibited a promising inhibitory effect: remdesivir, an experimental drug developed for the treatment of Ebola virus infection^{41,64}, and hydroxychloroquine, a drug known for its effectiveness in the treatment of malaria and autoimmune diseases⁴¹. Remdesivir is an adenosine triphosphate analogue initially described in the literature in 2016 as a potential treatment for Ebola⁶⁵, and this drug has been indeed considered as a potential treatment for SARS-CoV2⁶⁴. Notably, remdesivir has demonstrated antiviral activity in the treatment of MERS and SARS⁶⁶ in animal models, both of which are caused by coronaviruses⁶⁷. Pharmacophore models are widely used in medicinal chemistry with the aim of amplifying the number of drug candidates, and according to this definition, they are represented by a 3D arrangement of abstract features instead of chemical groups⁶⁸. Remdesivir is a nucleotide analogue with capacity to inhibit RNA polymerase (Table 1): this molecule displayed almost the same pharmacophoric features (Figure 1) as for N3 and OEW, and, besides, both of them have already tested experimentally. Additionally, as can be seen in Table 2, the best hit is ZINC1875405, which was found in both OEW and remdesivir pharmacophore searching, and this could be explained by their similar characteristics. Hydroxychloroquine is an aminoquinoline-like chloroquine⁶⁹. It is a drug commonly prescribed for the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus⁷⁰. Chloroquine and hydroxychloroquine have been investigated for the treatment of SARS-CoV-2⁷¹, and they have been reported to have direct antiviral effects, such as inhibition of flaviviruses, retroviruses (like HIV), and many coronaviruses. Additionally, hydroxychloroquine is capable of inhibiting the zika virus NS2B-NS3 protease, and exhibited good viral replication blocking in infected JEG3 cells in concentration of 80 μ M of hydroxychloroquine⁷². Furthermore, the use of chloroquine and its analogues can be corroborated by a recent study showing that, with EC₅₀ of 1.13 μ mol/L and selectivity index (SI) greater than 88, chloroquine can effectively inhibit SARS-CoV-2 at the cellular

level⁷³. Its effectiveness in the human body for SARS-CoV-2 infection; however, has not yet been clinically proven. Another *in silico* study with chloroquine detected its interactions with viral NSP-3B type protease⁷⁴.

The co-crystallized molecules N3 and OEW are both peptide analogs, which presented RMSD values of 1.94 Å and 1.97 Å in re-docking experiments, respectively. Generally, docking validations protocols use co-crystallized ligands, to test the accuracy of the program to predict the correct ligand docking poses in comparison to known conformations, and its RMSD varies 1.5 or 2 Å depending on ligand size for being considering acceptable⁷⁵. The number of studies using protein-peptide docking has been increasing rapidly, followed by the number of applied drug design programs and models. On the other hand, the use of RMSD validations with experimental structures is not always the best criterion of docking success, once it can be influenced by resolution quality, as well as the number of peptide residues⁷⁶. Thus, we can consider that N3 and OEW docking validations are in acceptable RMSD ranges.

Conclusions

In our study, we compared the pharmacophores of four well-tested human coronavirus (including SARS-Cov-2) main protease drug candidates to 50,000 structures of natural compounds from the ZINC Database. The three best molecules selected for each pharmacophore class are mainly classified as β -carboline alkaloids, and polyflavonoids. The best ligand-SARS-CoV-2 complexes exhibited better affinity energies in comparison to drug molecules used in this study. Furthermore, all the screened molecules bonded between domains -I and -II and formed interactions with the catalytic residues HIS41 and CYS145 in similar positions as previously described from other authors in viral protease inhibitor studies. Altogether, we propose these compounds as possible SARS-CoV-2 protease inhibitors, which can be used for subsequent *in vitro* and *in vivo* tests for finding novel drug candidates.

Data availability

Source data

Structures of natural compounds were downloaded from the [ZINC Database](#).

Crystal structures of COVID-19 main protease were downloaded from the Protein Data Bank, accession numbers [6LU7](#) (in complex with N3) and [6Y7M](#) (with OEW).

Extended data

Harvard Dataverse: Replication Data for: Computational screening for potential drug candidates against SARS-CoV-2 main protease. <https://doi.org/10.7910/DVN/GYFXA0>⁶¹.

This project contains the following extended data:

- 2D interaction maps of all OEW pharmacophore-like ligands (PNG).
- 2D interaction maps of all Remdesivir pharmacophore-like ligands (PNG).
- 2D interaction maps of all Hydroxychloroquine pharmacophore-like ligands (PNG).
- 2D interaction maps of all N3 pharmacophore-like ligands (PNG).

Extended data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

Acknowledgements

We would like to thank The OpenEye Science for the OpenEye Software license, which made possible the ligand based virtual screening experiments.

This research was developed with the help of the Núcleo de Biologia Computacional e Gestão de Informações Biotecnológicas- NBCGIB “, with resources from FINEP / MCT, CNPQ and FAPESB and from Universidade Estadual de Santa Cruz – UESC, represented by Dr. Eduardo Almeida Costa. Additionally, the authors would like to acknowledge the SENAI CIMATEC Center for Industrial Innovation, with support from BG Brazil and the Brazilian Authority for Oil, Gas and Biofuels (ANP), for the provision and operation of computational facilities and the commitment to invest in Research & Development.

References

- Cui J, Li F, Shi ZL: **Origin and evolution of pathogenic coronaviruses.** *Nat Rev Microbiol.* 2019; **17**(3): 181–192.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Schoeman D, Fielding BC: **Coronavirus envelope protein: current knowledge.** *Virol J.* 2019; **16**(1): 69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Peiris JS, Guan Y, Yuen KY: **Severe acute respiratory syndrome.** *Nat Med.* 2004; **10**(12 Suppl): S88–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zaki AM, Van Boheemen S, Bestebroer TM, *et al.*: **Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.** *N Engl J Med.* 2012; **367**(19): 1814–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Benvenuto D, Giovanetti M, Ciccozzi A, *et al.*: **The 2019-new coronavirus epidemic: Evidence for virus evolution.** *J Med Virol.* 2020; **92**(4): 455–459.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wu F, Zhao S, Yu B, *et al.*: **A new coronavirus associated with human respiratory disease in China.** *Nature.* 2020; **579**(7798): 265–269.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zheng M, Gao Y, Wang G, *et al.*: **Functional exhaustion of antiviral lymphocytes in COVID-19 patients.** *Cell Mol Immunol.* 2020; **17**(5): 533–535.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

8. Jin Z, Du X, Xu Y, *et al.*: **Structure of M^{pro} from COVID-19 virus and discovery of its inhibitors.** *Nature*. 2020.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Bzowska M, Mitusińska K, Raczynska A, *et al.*: **Molecular Dynamics Simulations Indicate the COVID-19 Mpro Is Not a Viable Target for Small-Molecule Inhibitors Design.** *bioRxiv*. 2020.
[Publisher Full Text](#)
10. Bzowska M, Mitusińska K, Raczynska A, *et al.*: **Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design.** *Int J Mol Sci*. 2020; 21(9): pii: E3099.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Cheng VC, Lau SK, Woo PC, *et al.*: **Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection.** *Clin Microbiol Rev*. 2007; 20(4): 660–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Guo YR, Cao QD, Hong ZS, *et al.*: **The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.** *Mil Med Res*. 2020; 7(1): 11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Hussain M, Galvin HD, Haw TY, *et al.*: **Drug resistance in influenza A virus: the epidemiology and management.** *Infect Drug Resist*. 2017; 10: 121–134.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. McKeegan KS, Borges-Walmsley MI, Walmsley AR: **Microbial and viral drug resistance mechanisms.** *Trends Microbiol*. 2002; 10(10 Suppl): S8–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Sharma A, Gupta SP: **Fundamentals of viruses and their proteases.** In: *Viral Proteases and Their Inhibitors*. 2017; 1–24.
[Publisher Full Text](#) | [Free Full Text](#)
16. Zhang T, Wu Q, Zhang Z: **Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak.** *Curr Biol*. 2020; 30(7): 1346–1351.e2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Patel S: **A critical review on serine protease: Key immune manipulator and pathology mediator.** *Allergol Immunopathol (Madr)*. 2017; 45(6): 579–591.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Anand K, Palm GJ, Mesters JR, *et al.*: **Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain.** *EMBO J*. 2002; 21(13): 3213–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Jin Z, Du X, Xu Y, *et al.*: **Structure of M^{pro} from COVID-19 virus and discovery of its inhibitors.** *bioRxiv*. 2020.
[Publisher Full Text](#)
20. Meng T, Cao H, Zhang H, *et al.*: **The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS.** *bioRxiv*. 2020.
[Publisher Full Text](#)
21. Kang S, Yang M, Hong Z, *et al.*: **Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites.** *bioRxiv*. 2020.
[Publisher Full Text](#)
22. Yang H, Yang M, Ding Y, *et al.*: **The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor.** *Proc Natl Acad Sci U S A*. 2003; 100(23): 13190–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Zhang P, Gao Q, Wang T, *et al.*: **Evaluation of recombinant nucleocapsid and spike proteins for serological diagnosis of novel coronavirus disease 2019 (COVID-19).** *medRxiv*. 2020.
[Publisher Full Text](#)
24. Xu X, Chen P, Wang J, *et al.*: **Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.** *Sci China Life Sci*. 2020; 63(3): 457–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Hoffmann M, Kleine-Weber H, Schroeder S, *et al.*: **SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.** *Cell*. 2020; 181(2): 271–280.e8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Zumla A, Chan JF, Azhar EI, *et al.*: **Coronaviruses - drug discovery and therapeutic options.** *Nat Rev Drug Discov*. 2016; 15(5): 327–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Crumpacker CS: **Use of Antiviral Drugs to Prevent Herpesvirus Transmission.** *N Engl J Med*. 2004; 350(1): 67–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Ter Heine R, Mulder JW, Van Gorp EC, *et al.*: **Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.** *Br J Clin Pharmacol*. 2010; 69(5): 475–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Balayan T, Horvath H, Rutherford GW: **Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review.** *AIDS Res Treat*. 2017; 2017: 2345617.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Mitjà O, Clotet B: **Use of antiviral drugs to reduce COVID-19 transmission.** *Lancet Glob Health*. 2020; 8(5): e639–e640.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Irwin JJ, Sterling T, Mysinger MM, *et al.*: **ZINC: A free tool to discover chemistry for biology.** *J Chem Inf Model*. 2012; 52(7): 1757–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Ghose AK, Viswanadhan VN, Wendoloski JJ: **A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases.** *J Comb Chem*. 1999; 1(1): 55–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Lipinski CA, Lombardo F, Dominy BW, *et al.*: **Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.** *Adv Drug Deliv Rev*. 2001; 46(1–3): 3–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Hawkins PCD, Skillman AG, Nicholls A: **Comparison of shape-matching and docking as virtual screening tools.** *J Med Chem*. 2007; 50(1): 74–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Schneidman-Duhovny D, Dror O, Inbar Y, *et al.*: **PharmaGist: a webserver for ligand-based pharmacophore detection.** *Nucleic Acids Res*. 2008; 36(Web Server issue): W223–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Rácz A, Bajusz D, Héberger K: **Life beyond the Tanimoto coefficient: Similarity measures for interaction fingerprints.** *J Cheminform*. 2018; 10(1): 48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Bajusz D, Rácz A, Héberger K: **Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations?** *J Cheminform*. 2015; 7: 20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Zhang L, Lin D, Sun X, *et al.*: **Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors.** *Science*. 2020; 368(6489): 409–412.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Morris GM, Dallakyan S: **AutoDock — AutoDock.** 2013.
[Reference Source](#)
40. Forli S, Huey R, Pique ME, *et al.*: **Computational protein-ligand docking and virtual drug screening with the AutoDock suite.** *Nat Protoc*. 2016; 11(5): 905–919.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Wang M, Cao R, Zhang L, *et al.*: **Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) *in vitro*.** *Cell Res*. 2020; 30(3): 269–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Schrödinger L: **The PyMol Molecular Graphics System, Versión 1.8.** Thomas Holder. 2015.
[Reference Source](#)
43. Pettersen EF, Goddard TD, Huang CC, *et al.*: **UCSF Chimera - A visualization system for exploratory research and analysis.** *J Comput Chem*. 2004; 25(13): 1605–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Discovery Studio: **Dassault Systemes BIOVIA, Discovery Studio Modelling Environment, Release 4.5.** Accelrys Softw Inc. 2015.
[Reference Source](#)
45. Laskowski RA, Swindells MB: **LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery.** *J Chem Inf Model*. 2011; 51(10): 2778–2786.
[Publisher Full Text](#)
46. Martinez MA: **Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.** *Antimicrob Agents Chemother*. 2020; 64(5): pii: e00399–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Gonzalez MM, Cabrerizo FM, Baiker A, *et al.*: **β -Carboline derivatives as novel antivirals for herpes simplex virus.** *Int J Antimicrob Agents*. 2018; 52(4): 459–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Ahmad I, Fatima I, Afza N, *et al.*: **Urease and serine protease inhibitory alkaloids from *Isatis tinctoria*.** *J Enzyme Inhib Med Chem*. 2008; 23(6): 918–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. ul Qamar MT, Mumtaz A, Ashfaq UA, *et al.*: **Potential of plant alkaloids as dengue ns3 protease inhibitors: Molecular docking and simulation approach.** *Bangladesh J Pharmacol*. 2014; 9(3): 262–7.
[Publisher Full Text](#)
50. Powers CN, Setzer WN: **An *In-Silico* Investigation of Phytochemicals as Antiviral Agents Against Dengue Fever.** *Comb Chem High Throughput Screen*. 2016; 19(7): 516536.
[Publisher Full Text](#)
51. Qamar MT, Ashfaq UA, Tusleem K, *et al.*: ***In-silico* identification and evaluation of plant flavonoids as dengue NS2B/NS3 protease inhibitors using molecular docking and simulation approach.** *Pak J Pharm Sci*. 2017; 30(6): 2119–37.
[PubMed Abstract](#)
52. Shimizu JF, Lima CS, Pereira CM, *et al.*: **Flavonoids from *Pterogyne nitens* Inhibit Hepatitis C Virus Entry.** *Sci Rep*. 2017; 7(1): 16127.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Hawas UW, Abou El-Kassem LT, Shafer F, *et al.*: ***In vitro* inhibition of Hepatitis C virus protease and antioxidant by flavonoid glycosides from the Saudi coastal**

- plant *Sarcocornia fruticosa*. *Nat Prod Res*. 2019; **33**(23): 3364–3371.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Kaul TN, Middleton E Jr, Ogra PL: **Antiviral effect of flavonoids on human viruses**. *J Med Virol*. 1985; **15**(1): 71–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. González-Búrquez MD, González-Díaz FR, García-Tovar CG, *et al.*: **Comparison between *in Vitro* Antiviral Effect of Mexican Propolis and Three Commercial Flavonoids against Canine Distemper Virus. Evidence-based Complement Altern Med**. 2018; **2018**: 7092416.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. Dai W, Bi J, Li F, *et al.*: **Antiviral Efficacy of Flavonoids against Enterovirus 71 Infection *in vitro* and in Newborn Mice**. *Viruses*. 2019; **11**(7): pii: E625.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 57. Tomlinson SM, Watowich SJ: **Anthracene-based inhibitors of dengue virus NS2B-NS3 protease**. *Antiviral Res*. 2011; **89**(2): 127–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Barnard DL, Xu Z, Stowell VD, *et al.*: **Coumarins and pyranocoumarins, potential novel pharmacophores for inhibition of measles virus replication**. *Antivir Chem Chemother*. 2002; **13**(1): 39–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. Hassan MZ, Osman H, Ali MA, *et al.*: **Therapeutic potential of coumarins as antiviral agents**. *Eur J Med Chem*. 2016; **123**: 236–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 60. Behbahani M, Sayedipour S, Pourazar A, *et al.*: ***In vitro* anti-HIV-1 activities of kaempferol and kaempferol-7-O-glucoside isolated from Securigera securidaca**. *Res Pharm Sci*. 2014; **9**(6): 463–9.
[PubMed Abstract](#) | [Free Full Text](#)
 61. Andrade B: **“Replication Data for: Computational screening for potential drug candidates against SARS-CoV-2 main protease”**. Harvard Dataverse, V1. 2020. <http://www.doi.org/10.7910/DVN/GYFXA0>
 62. Ren Z, Yan L, Zhang N, *et al.*: **The newly emerged SARS-Like coronavirus HCoV-EMC also has an “Achilles” heel”: Current effective inhibitor targeting a 3C-like protease”**. *Protein Cell*. 2013; **4**(4): 248–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 63. Dai W, Zhang B, Su H, *et al.*: **Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease**. *Science*. 2020; pii: eabb4489.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 64. de Wit E, Feldmann F, Cronin J, *et al.*: **Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection**. *Proc Natl Acad Sci U S A*. 2020; **117**(12): 6771–6776.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. Warren TK, Jordan R, Lo MK, *et al.*: **Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys**. *Nature*. 2016; **531**(7594): 81–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 66. Gordon CJ, Tchesnokov EP, Feng JY, *et al.*: **The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus**. *J Biol Chem*. 2020; **295**(15): 4773–4779.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. Sheahan TP, Sims AC, Graham RL, *et al.*: **Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses**. *Sci Transl Med*. 2017; **9**(396): pii: eaal3653.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 68. Kaserer T, Beck KR, Akram M, *et al.*: **Pharmacophore models and pharmacophore-based virtual screening: Concepts and applications exemplified on hydroxysteroid dehydrogenases**. *Molecules*. 2015; **20**(12): 22799–832.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 69. Furst DE: **Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases**. *Lupus*. 1996; **5** Suppl 1: S11–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Shippey EA, Wagler VD, Collamer AN: **Hydroxychloroquine: An old drug with new relevance**. *Cleve Clin J Med*. 2018; **85**(6): 459–467.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Devaux CA, Rolain JM, Colson P, *et al.*: **New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?** *Int J Antimicrob Agents*. 2020; 105938.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 72. Kumar A, Liang B, Aarthy M, *et al.*: **Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease**. *ACS Omega*. 2018; **3**(12): 18132–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 73. Wang Q, Zhang Y, Wu L, *et al.*: **Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2**. *Cell*. 2020; pii: S0092-8674(20)30338-X.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 74. Wu C, Liu Y, Yang Y, *et al.*: **Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods**. *Acta Pharm Sin B*. 2020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 75. Hevener KE, Zhao W, Ball DM, *et al.*: **Validation of molecular docking programs for virtual screening against dihydropteroate synthase**. *J Chem Inf Model*. 2009; **49**(2): 444–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 76. Ciemny M, Kurcinski M, Kamel K, *et al.*: **Protein-peptide docking: opportunities and challenges**. *Drug Discov Today*. 2018; **23**(8): 1530–7.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 09 December 2020

<https://doi.org/10.5256/f1000research.26292.r75869>

© 2020 Aljabali A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alaa A A Aljabali

¹ Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid, Jordan

² Yarmouk University, Irbid, Jordan

The manuscript is well written, balanced, and follows the scientific logic and flow very nicely. The work is very novel and holds great potential. The approach is very useful and holds great potential in using the docking system to maybe identify new antiviral candidates in this pandemic.

Some minor comments:

1. Please list the software used for generating the docking work.
2. Could you please improve the figure axis of 6 bars for clarity (B and E)?
3. Could you please add a short paragraph on the novelty of this approach of molecular docking?
4. Could you please indicate if any of the reported drugs have been used in clinical trials originated from the docking approach?
5. Would it be possible to show the pharmacophore score for both acceptors and donors for ZINC?

Some key reference should be included in the manuscript:

1. COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics¹.
2. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development².
3. The Structural Basis of Accelerated Host Cell Entry by SARS-CoV-2³.
4. Questions concerning the proximal origin of SARS-CoV-2⁴.

References

1. Amawi H, Abu Deiab GI, A Aljabali AA, Dua K, et al.: COVID-19 pandemic: an overview of

epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. *Ther Deliv.* **11** (4): 245-268 [PubMed Abstract](#) | [Publisher Full Text](#)

2. Aljabali AAA, Bakshi HA, Satija S, Metha M, et al.: COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. *Pharm Nanotechnol.* 2020; **8** (4): 323-353 [PubMed Abstract](#) | [Publisher Full Text](#)

3. Seyran M, Takayama K, Uversky VN, Lundstrom K, et al.: The Structural Basis of Accelerated Host Cell Entry by SARS-CoV-2†. *FEBS J.* 2020. [PubMed Abstract](#) | [Publisher Full Text](#)

4. Seyran M, Pizzol D, Adadi P, El-Aziz T, et al.: Questions concerning the proximal origin of SARS-CoV-2. *Journal of Medical Virology.* 2020. [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: viral nanotechnology, biotechnology and drug delivery

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 15 Dec 2020

Bruno Andrade

The manuscript is well written, balanced, and follows the scientific logic and flow very nicely. The work is very novel and holds great potential. The approach is very useful and holds great potential in using the docking system to maybe identify new antiviral candidates in this pandemic.

We would like to thank you very much for your description of our work. We improved the paper based on your recommendations.

Some minor comments:

Please list the software used for generating the docking work.

The docking protocol is described in the Methods section (Docking Studies subsection)

Could you please improve the figure axis of 6 bars for clarity (B and E)?

Figure 6 (B and E) is part of Autodock 4 results, visualized at Autodock Tools program. This program doesn't give us a good resolution docking energy graph. We improved the figure quality using an image editor program in this new version. Thank you for your suggestion.

Could you please add a short paragraph on the novelty of this approach of molecular docking?

Our focus in this work was using pharmacophore modeling in order to find new possible ligand Mpro inhibitors, as well as repurpose approved drugs for SARS-CoV-2. In this case, we used a common docking approach for confirming our pharmacophore predictions. All docking protocol is described in the Methods section. Thank you very much for your suggestion.

Could you please indicate if any of the reported drugs have been used in clinical trials originated from the docking approach?

All molecules used for pharmacophore generation were tested in vitro, in vivo, and in silico. We included four citations for the in silico tests in the discussion section.

Would it be possible to show the pharmacophore score for both acceptors and donors for ZINC?

We used OpenEye vROCS program, which considers the Tanimoto Combo (TC) scores for selecting the most similar pharmacophore-like molecules. We included a column in table 2, showing the TC score for each best-selected ligand. Thank you very much for this suggestion.

Some key reference should be included in the manuscript:

COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics¹.

We included the suggested reference in this new version. Thank you.

COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development².
The Structural Basis of Accelerated Host Cell Entry by SARS-CoV-23.
Questions concerning the proximal origin of SARS-CoV-24.

We included the suggested reference in this new version. Thank you.

References included

1. Amawi H, Abu Deiab GI, A Aljabali AA, Dua K, Tambuwala MM. COVID-19 pandemic: An overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. *Therapeutic Delivery*. 2020.
2. Aljabali AAA, Bakshi HA, Satija S, Metha M, Prasher P, Ennab RM, et al. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. *Pharm Nanotechnol*. 2020;
3. Hagar M, Ahmed HA, Aljohani G, Alhaddad OA. Investigation of some antiviral N-heterocycles as COVID 19 drug: Molecular docking and DFT calculations. *Int J Mol Sci*. 2020;
4. C S, S DK, Ragunathan V, Tiwari P, A S, Brindha Devi BD. Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease. *J Biomol Struct Dyn*. 2020;
5. Naik VR, Munikumar M, Ramakrishna U, Srujana M, Goudar G, Naresh P, et al. Remdesivir (GS-5734) as a therapeutic option of 2019-nCoV main protease-in silico approach. *J Biomol Struct Dyn*. 2020;
6. Peele KA, Potla Durthi C, Srihansa T, Krupanidhi S, Ayyagari VS, Babu DJ, et al. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. *Informatics Med Unlocked*. 2020;

Competing Interests: No competing interests were disclosed.

Reviewer Report 09 December 2020

<https://doi.org/10.5256/f1000research.26292.r75868>

© 2020 Tambuwala M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Murtaza M. Tambuwala

School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, UK

"Computational screening for potential drug candidates against the SARS-CoV-2 main protease" is overall a timely interesting review focused on COVID pandemic.

However, since the literature on COVID research is being updated so rapidly this review seems to have used older references and some latest and relevant papers have been missed out.

Below I have provided suggestions for several such manuscripts that need to be included and discussed:

- The Structural Basis of Accelerated Host Cell Entry by SARS-CoV-2¹.
- The Importance of Research on the Origin of SARS-CoV-2².
- Questions concerning the proximal origin of SARS-CoV-2³.

- Probing 3CL protease: Rationally designed chemical moieties for COVID-19⁴.
- COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics⁵.
- COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development⁶.

I am confident that this review will attract a good level of readership from both the public and the research community.

References

1. Seyran M, Takayama K, Uversky VN, Lundstrom K, et al.: The Structural Basis of Accelerated Host Cell Entry by SARS-CoV-2†. *FEBS J*. 2020. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Lundstrom K, Seyran M, Pizzol D, Adadi P, et al.: The Importance of Research on the Origin of SARS-CoV-2. *Viruses*. 2020; **12** (11). [Publisher Full Text](#)
3. Seyran M, Pizzol D, Adadi P, El-Aziz T, et al.: Questions concerning the proximal origin of SARS-CoV-2. *Journal of Medical Virology*. 2020. [Publisher Full Text](#)
4. Sharma M, Prasher P, Mehta M, Zacconi FC, et al.: Probing 3CL protease: Rationally designed chemical moieties for COVID-19. *Drug Dev Res*. 2020. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Amawi H, Abu Deiab GI, Aljabali AA, Dua K, et al.: COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. *Ther Deliv*. **11** (4): 245-268 [PubMed Abstract](#) | [Publisher Full Text](#)
6. Aljabali AAA, Bakshi HA, Satija S, Metha M, et al.: COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. *Pharm Nanotechnol*. 2020; **8** (4): 323-353 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Inflammation, cancer, and infections research

I confirm that I have read this submission and believe that I have an appropriate level of

expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research